ClinicalTrials.gg
Not yet recruitingNCT05054231SI-CARTUpdated Oct 15, 2021

Immunological Profile for Patients Treated With CAR-T Cells

An interventional study of Blood sample collection in Hematologic Neoplasms, sponsored by Institut Paoli-Calmettes. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-15.

Sponsored by Institut Paoli-Calmettes · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
500
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Hematologic Neoplasms by Institut Paoli-Calmettes — 4 open to participants now, 4 under way, none of them phase 3. Hematologic Neoplasms · Institut Paoli-Calmettes.

Started
2021
with 1 other
No phase
3 of 10
2 open now
Registered
5th of 10
by date

Among the 10 studies in Hematologic Neoplasms by Institut Paoli-Calmettes, this one is one of 2 that started in 2021, is one of 3 with no phase, and was the 5th registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

4 of the 10 studies in Hematologic Neoplasms by Institut Paoli-Calmettes are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Hematologic Neoplasms by Institut Paoli-Calmettes, or all of them as a file.
02

Study summary

In the frame of Si-CART study, blood will be collected from patients treated with CAR-T cells: before (at Day (D)-6 and D0 before cells injection), post infusion at D3, D5,D7, D9, D11, D14, D18, D 21, Month (M) 2 and M12 post injection.

A cerebrospinal fluid sample will also be collected if a Cerebrospinal Fluid Analysis Lumbar puncture is performed

03

Conditions studied

  • Hematologic Neoplasms

Keywords

  • CAR-T cells
  • Immunological Profile
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Planned injection of CAR-T cells within the scope of marketing authorization
  • Signed
  • French social security affiliation

Exclusion criteria

Exclusion Criteria:

  • Pregnant women, or women of (without medically acceptable ) or breastfeeding women.
  • Patient in emergency situation, adult under legal protection (patient placed under tutorship, curatorship, or judicial protection) or unable to give his consent
  • Impossibility to comply with trial medical follow-up for geographic, social or psychological reasons
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    Patient treated with CAR-T cells

    Other: Blood sample collection

Interventions

  • OtherBlood sample collection

    Blood samples collection: at Day (D)-6 and D0 before CAR-T cells injection, post injection at Day (D)3, D5,D7, D9, D11, D14, D18, D 21, Month 2 and Month 12 post injection.

06

What researchers measure

Primary outcomes

  1. Correlation between serum markers and adverse events at 1 year of the CAR-T cells infusion

    Serum concentration of cytokines in relation to adverse events

    Time frame: 1 year after T cells infusion

Secondary outcomes

  1. CAR-T cells rate from infusion to one year after CAR-T cells infusion

    Flow cytometry

    Time frame: From CAR-T cells infusion to one year

  2. Number of participants with a relapse

    Relapse rate from CAR-T cells infusion to one year

    Time frame: From CAR-T cells infusion to one year

  3. Number of participants with a cytokine release syndrome

    Cytokine release syndrome from CAR-T cells infusion to one year

    Time frame: From CAR-T cells infusion to one year

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2021; primary completion for Oct 2025, 48 months later.

Of 186 non-industry interventional studies with no phase under Hematologic Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 125. This study's planned 48 months is above that.

Counting every sponsor, half of 192 studies reached it within 40 months; a quarter within 21 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2020
First posted
Sep 23, 2021
StartEst.
Oct 5, 2021
Primary completionEst.
Oct 5, 2025
CompletionEst.
Oct 5, 2026
Last update
Oct 15, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05054231
Responsible party
Sponsor
First posted
Sep 23, 2021
Start date
Oct 5, 2021 (estimated)
Primary completion
Oct 5, 2025 (estimated)
Completion
Oct 5, 2026 (estimated)
Last update
Oct 15, 2021

Study contacts

Dominique GENRE, MD
Contact
drci.up@ipc.unicancer.fr
+33491223778
Jihane PAKRADOUNI, Pharm PhD
Contact
pakradounij@ipc.unicancer.fr
+33491223778

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion